statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP - Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $10.00 target...

Cocrystal Pharma (NASDAQ:COCP) Stock Rating Reaffirmed by HC Wainwright

Cocrystal Pharma, Inc. (NASDAQ:COCP - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cocrystal Pharma in a research report...

Cocrystal Pharma, Inc. (NASDAQ:COCP) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cocrystal Pharma sees cash runway beyond next 12 months

Cocrystal Pharma reports 2023 EPS ($1.87), consensus ($2.09)

FDA feedback following the Company's submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma GAAP EPS of -$1.87

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
COCP stock results show that Cocrystal Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
The post COCP...

COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023

Recap: Cocrystal Pharma Q4 Earnings

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ( Cocrystal or...

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage...

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Watchers	16,244
52-Wk Low	$1.33
52-Wk High	$3.29

Volume	33,026.00
52-Wk High	$3.29
52-Wk Low	$1.33

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.48	--	--	N/A
Q1'24	-$0.54	-$0.39	27.78%	BEAT
Q4'23	-$0.57	-$0.32	43.36%	BEAT
Q3'23	-$0.53	-$0.41	22.64%	BEAT
Q2'23	-$0.58	-$0.50	13.79%	BEAT

COCP Cocrystal Pharma Inc

About

Feed

News

Earnings

Fundamentals